Clinical Focus
Previous Articles Next Articles
Online:
Published:
Contact:
Abstract: Objective To observe the protective effect of calcium dibutyryladenosine cyclophosphate in subacute cardiotoxicity induced by doxorubicin chemotherapy. Methods Totally 47 cases of breast cancer and lymphoma were randomly divided into control group(n=23) and treatment group(n=24). Both groups received the chemotherapy regimens containing doxorubicin and the treatment group had an addition injection of calcium dibutyryladenosine cyclophosphate. Both groups received four complete cycles of chemotherapy. The ECG changes, echocardiography (left ventricular ejection fraction, LVEF), Nterminal probrain natriuretic peptide (NTproBNP), cardiac troponin I (cTnI) and CKMB values in both groups were observed before the chemotherapy and after two and four cycle chemotherapy.Results Upon comparing the ECG changes, LVEF, cTnI, NTproBNP and CKMB values of both groups before 48 hours of the chemotherapy and after one week of two and four cycle chemotherapy, treatment group had lesser incidence rates in abnormal ECG, decreased LVEF, increased cTnI, NTproBNP and CKMB (P<0.05). Conclusion Calcium dibutyryladenosine cyclophosphate may reduce the cardiotoxicity induced by doxorubicin chemotherapy.
Key words: breast neoplasms, lymphoma, cardiotoxins, doxorubicin, calcium dibutyryladenosini cyclophosphas
Miao Yandong, Quan Wuxia. Clinical study of calcium dibutyryladenosine cyclophosphate in prevention of subacute cardiotoxicity induced by doxorubicin chemotherapy[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2017.12.009.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2017.12.009
https://huicui.hebmu.edu.cn/EN/Y2017/V32/I12/1053